Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$116.17 USD

116.17
1,326,898

+0.71 (0.61%)

Updated Sep 3, 2024 04:00 PM ET

After-Market: $116.20 +0.03 (0.03%) 7:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Trina Mukherjee headshot

3 Stocks to Capitalize on Promising Medical Products Industry

by Trina Mukherjee

Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Zimmer Biomet (ZBH) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 72.38% and 12.50%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Stock Earnings on Nov 6: ZBH, HRC and HMSY

by Urmimala Biswas

Several medical product stocks have come up with bullish earnings reports so far this reporting cycle. Let's see how ZBH, HRC and HMS are poised ahead of their announcements.

Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Trina Mukherjee headshot

3 Medical Product Stocks Poised to Beat This Earnings Season

by Trina Mukherjee

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, on the back of several factors.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) Dental product volumes are expected to have declined significantly in the third quarter due to the extremely elective nature of the products.

Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in Pharmaceutical segment.

What's in Store for Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) fiscal fourth-quarter results likely to reflect robust performance at BD Life Sciences.

DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect weak segmental performance.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Invitae (NVTA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q3.

Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

McKesson (MCK) to Post Q2 Earnings: What's in the Offing?

by Zacks Equity Research

McKesson's (MCK) fiscal second-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

OPKO Health (OPK) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

OPKO Health's (OPK) third-quarter results are likely to reflect solid performance from Products segment and RAYALDEE.

Livongo Health (LVGO) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Livongo Health's (LVGO) third-quarter results are likely to reflect growth in core Livongo for Diabetes solution.

Baxter (BAX) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) third-quarter performance is likely to reflect growth in its Acute Therapies business.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) third-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Here's Why You Should Add Globus Medical to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Globus Medical (GMED) on robust product uptake and prominent sales trend improvement since the second quarter.

Debanjana Dey headshot

4 MedTech Growth Stocks With Strong ROE to Buy Amid Coronavirus

by Debanjana Dey

Here are some MedTech growth stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.

The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Medtronic, Abbott Laboratories, Myriad Genetics, Zimmer Biomet and General Electric

Zimmer (ZBH) Up 7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Urmimala Biswas headshot

3 Coronavirus-Led Threats to MedTech That May Linger

by Urmimala Biswas

Let us delve deeper to get an insight into the not-so-talked-about but intense threats to MedTech.

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

by Zacks Equity Research

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 106.94% and 31.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?